Novel androgen therapies including selective androgen receptor modulators

Best Pract Res Clin Endocrinol Metab. 2022 Sep;36(5):101686. doi: 10.1016/j.beem.2022.101686. Epub 2022 Jul 30.

Abstract

Male hypogonadism is associated with reduced quality of life and the development of co-morbidities including obesity, diabetes mellitus, and dyslipidaemia. The mainstay of treatment for male hypogonadism is testosterone replacement therapy (TRT). However, TRT has recognised side effects including impaired spermatogenesis and there are concerns regarding its use in men with concurrent cardiovascular disease. Thus, there has been an impetus to develop novel androgen therapies for treating male hypogonadism to mitigate the side effects of TRT. This review will discuss the benefits and adverse effects of TRT, and novel therapies including nasal testosterone, aromatase inhibitors, selective oestrogen receptor modulators, and selective androgen receptor modulators.

Keywords: male hypogonadism; nasal testosterone; novel androgen therapies; testosterone replacement therapy.

Publication types

  • Review

MeSH terms

  • Androgen Receptor Antagonists* / adverse effects
  • Androgen Receptor Antagonists* / therapeutic use
  • Androgens* / adverse effects
  • Androgens* / therapeutic use
  • Aromatase Inhibitors* / adverse effects
  • Aromatase Inhibitors* / therapeutic use
  • Hormone Replacement Therapy*
  • Humans
  • Hypogonadism* / drug therapy
  • Male
  • Quality of Life
  • Receptors, Androgen
  • Selective Estrogen Receptor Modulators* / adverse effects
  • Selective Estrogen Receptor Modulators* / therapeutic use
  • Testosterone

Substances

  • Androgen Receptor Antagonists
  • Androgens
  • Aromatase Inhibitors
  • Receptors, Androgen
  • Selective Estrogen Receptor Modulators
  • Testosterone